ATE356635T1 - Verfahren zur vorbeugung oder behandlung von benignen gynäkologischen störungen - Google Patents

Verfahren zur vorbeugung oder behandlung von benignen gynäkologischen störungen

Info

Publication number
ATE356635T1
ATE356635T1 AT02780166T AT02780166T ATE356635T1 AT E356635 T1 ATE356635 T1 AT E356635T1 AT 02780166 T AT02780166 T AT 02780166T AT 02780166 T AT02780166 T AT 02780166T AT E356635 T1 ATE356635 T1 AT E356635T1
Authority
AT
Austria
Prior art keywords
benigus
treating
preventing
gynecological disorders
progestogen
Prior art date
Application number
AT02780166T
Other languages
English (en)
Inventor
Bennink Herman Jan Ti Coelingh
Monique Visser
Original Assignee
Pantarhei Bioscience Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pantarhei Bioscience Bv filed Critical Pantarhei Bioscience Bv
Application granted granted Critical
Publication of ATE356635T1 publication Critical patent/ATE356635T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02780166T 2001-11-15 2002-11-14 Verfahren zur vorbeugung oder behandlung von benignen gynäkologischen störungen ATE356635T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01204379 2001-11-15

Publications (1)

Publication Number Publication Date
ATE356635T1 true ATE356635T1 (de) 2007-04-15

Family

ID=8181247

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02780166T ATE356635T1 (de) 2001-11-15 2002-11-14 Verfahren zur vorbeugung oder behandlung von benignen gynäkologischen störungen

Country Status (10)

Country Link
US (2) US8071576B2 (de)
EP (1) EP1443966B1 (de)
AT (1) ATE356635T1 (de)
CA (1) CA2467237C (de)
CY (1) CY1106610T1 (de)
DE (1) DE60218881T2 (de)
DK (1) DK1443966T3 (de)
ES (1) ES2281551T3 (de)
PT (1) PT1443966E (de)
WO (1) WO2003041741A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030356A1 (fr) 1999-10-25 2001-05-03 Laboratoire Theramex Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation
MXPA04005864A (es) * 2001-12-19 2004-10-29 Atherogenics Inc Derivados de charcona y su uso para tratar enfermedades.
JP5616233B2 (ja) 2008-01-24 2014-10-29 エスペランス ファーマシューティカルズＥｓｐｅｒａｎｃｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ 溶解ドメイン融合コンストラクト及びその生成及び使用方法
US10913767B2 (en) 2010-04-22 2021-02-09 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs
US20130260460A1 (en) 2010-04-22 2013-10-03 Isis Pharmaceuticals Inc Conformationally restricted dinucleotide monomers and oligonucleotides
BRPI1003661A2 (pt) * 2010-09-15 2013-01-08 Libbs Farmaceutica Ltda associaÇço farmacÊutica para tratar e/ou prevenir mioma e/ou endometriose, uso de resveratrol e progestogenio, composiÇço farmacÊutica para tratamento e/ou prevenÇço de mioma e/ou endometriose medicamento para tratamento e/ou prevenÇço de mioma e/ou endometrios, kit e mÉtodo para tratamento e/ou prevenÇço de mioma e/ou endometriose
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
HRP20211377T1 (hr) 2011-11-23 2022-01-07 Therapeuticsmd, Inc. Prirodne kombinirane hormonske supstitucijske formulacije i terapije
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AU2013337926B2 (en) 2012-10-30 2017-12-21 Esperance Pharmaceuticals, Inc. Antibody/drug conjugates and methods of use
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
JP2019513709A (ja) 2016-04-01 2019-05-30 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． ステロイドホルモン薬学的組成物
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3608075A (en) * 1969-07-28 1971-09-21 American Home Prod Compositions and methods of treating the menopausal syndrome
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
AU5855794A (en) * 1993-01-19 1994-08-15 Endorecherche Inc. Therapeutic uses and delivery systems of dehydroepiandrosterone
US6139873A (en) * 1996-07-10 2000-10-31 Cedars-Sinai Medical Center Combined pharmaceutical estrogen-androgen-progestin
GB9616700D0 (en) * 1996-08-09 1996-09-25 Carey Beverly J Hormone supplement
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
US20030004145A1 (en) * 2001-05-16 2003-01-02 Leonard Thomas W. Treatment of conditions relating to hormone deficiencies by administration of progestins
US20030022875A1 (en) * 2001-07-27 2003-01-30 Wilson Leland F. As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness

Also Published As

Publication number Publication date
CA2467237A1 (en) 2003-05-22
EP1443966B1 (de) 2007-03-14
DE60218881D1 (de) 2007-04-26
PT1443966E (pt) 2007-06-21
CA2467237C (en) 2011-09-20
US20050148559A1 (en) 2005-07-07
WO2003041741A1 (en) 2003-05-22
EP1443966A1 (de) 2004-08-11
ES2281551T3 (es) 2007-10-01
CY1106610T1 (el) 2012-01-25
DK1443966T3 (da) 2007-05-21
US8071576B2 (en) 2011-12-06
US20120015917A1 (en) 2012-01-19
DE60218881T2 (de) 2007-12-20

Similar Documents

Publication Publication Date Title
ATE356635T1 (de) Verfahren zur vorbeugung oder behandlung von benignen gynäkologischen störungen
JP2019163318A5 (de)
RU2007148080A (ru) Составы и способы для лечения симптомов, связанных с циклом
KR970704450A (ko) 자궁내막증식증 또는 자궁평활근종을 치료하기 위한 프로게스테론 길항제 및 게스타겐의 용도(Use of a Progesterone Antagonist and of a Gestagen for the Treatment of Endometriosis or Leiomyomate Uteri)
HUP0301813A2 (hu) Nem-orális androgén szteroidok
RS20060348A (en) Extended use combination comprising estrogens and progestins
PL2131847T3 (pl) Lek zawierający przynajmniej jeden gestagen
CY1104981T1 (el) Χρηση των αντιπρογεστερονων για προληψη και αντιμετωπιση των εξαρτωμενων απο ορμονες ασθενειων
RU2008138166A (ru) Композиция, содержащая комбинацию ингибитора ароматазы, прогестина и эстрогена, и ее применение для лечения эндометриоза
ATE270554T1 (de) Kombination der progesteron und mifepristone für krebs-therapie
HUP9904345A2 (hu) Orális fogamzásgátló
ATE249222T1 (de) Biphasische orale verhuetungsmethode und kit die eine kombination von progestin und eines oestrogens enthalten
EP1286666A2 (de) Starterkit von niedrigdosiertem oralem kontrazeptiv
BRPI0511864A (pt) uso de uma combinação de etinilestradiol e acetato de clormadinona para a preparação de um medicamento
DE502006000771D1 (de) Feste perorale arzneiform zur kontrazeption, die dienogest und ethinylestradiol enthält
EA200501739A1 (ru) Композиция, содержащая антагонисты рецептора прогестерона и чистые антиэстрогены, предназначенные для профилактики и лечения гормонзависимых заболеваний
DE60209248D1 (de) Verwendung von (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propinyl)-estra-4,9-dien-3-on zur behandlung von schweren depressionen
MX2007009061A (es) Preparacion farmaceutica para la anticoncepcion oral.
HUP9901474A2 (hu) Szekvenciális ösztrogén/progeszteron-antagonista kombináció hormonhelyettesítő terápiához
DE50109175D1 (de) 4-halogenierte 17-methylensteroide, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
CY1112775T1 (el) Χρηση βαλεριανικης οιστραδιολης σε συνδυασμο με dienogest για την απο του στοματος θεραπεια της δυσλειτουργικης αιμορραγιας της μητρας σε ενοτητα με αντισυλληψη απο του στοματος
Robb-Nicholson By the way, doctor. I am 47 and have been taking Loestrin 1/20 for the past seven months. After the first month, I ceased having periods, which my gynecologist says is typical. Could you comment on why this happens and whether I am putting myself at increased risk for uterine cancer?
JP2005518412A5 (de)
TH134365B (th) โดรสไพริโนนสำหรับการรักษาด้วยการแทนที่ฮอร์โมน
TH84327B (th) การใช้และชุดสำเร็จรูปแอนโดรเจนสเตอรอยด์ (Androgenic Steriod) แบบที่ไม่ใช้รับประทานในสุภาพสตรี

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1443966

Country of ref document: EP